Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FiberChoice recall

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline announces March 20 it is recalling 144,000 bottles of FiberChoice Plus Multivitamins because fish gelatin, a known allergen, was not declared on the label. The recall affects 90-count, 16 oz. bottles that began shipping to retailers Jan. 15. No reports of adverse reactions had been reported as of the recall announcement. The Food Allergen Labeling Consumer Protection Act of 2004 requires that manufacturers of dietary supplements disclose major food allergens on product labeling (1"The Tan Sheet" Oct. 24, 2005, p. 10). GSK completed its acquisition of FiberChoice manufacturer CNS in December 2006 (2"The Tan Sheet" Jan. 1, 2007, In Brief)...

You may also be interested in...

FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens

Manufacturers of dietary supplements are required to begin labeling products that contain major food allergens on Jan. 1 in order to comply with the Food Allergen Labeling & Consumer Protection Act of 2004 (FALCPA)

2022 Korean VC Financings Led By Mid-Stage Bioventures

Amid a generally harsh environment, venture capital investors in South Korea appeared to take a more selective approach in 2022, with more established and financially stable domestic bioventures the biggest beneficiaries.

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts